A revolution in metastatic breast cancer diagnostics

When tissue biopsy results are not attainable, DefineMBC provides a comprehensive cancer profile that includes both cell-based and cell-free analysis

  • Circulating tumor cell immunofluorescent staining evaluates ER and HER2 protein expression

  • Single-cell genomics enables the detection of ERBB2 amplification from the nuclei of cancer cells

  • ctDNA analysis includes the assessment of microsatellite instability and tumor mutational burden as well as important genomic alterations (SNV, CNV, fusions) across 56 relevant genes

  • DefineMBC confirms metastatic breast cancer and identifies potential therapeutic targets that otherwise would go undetected with current liquid biopsies that rely on DNA sequencing alone

  • Multiple analyses result in a comprehensive clinical report that can be viewed here

DefineMBC potentially can provide information for optimal treatment decision-making at every line of therapy

Enroll in the DefineMBC Early Access Program today

Join a select group of oncologists and institutions who are at the leading edge of MBC diagnostic technology applying comprehensive cancer profiling and pursuing better treatment outcomes.

Please provide information below.


DefineMBC, The Power of Clarity, and the stylized “e” are trademarks of Epic Sciences, Inc. registered in the United States.
©2021 Epic Sciences